1. Mesenchymal Stromal Cells: What Is the Mechanism in Acute Graft-Versus-Host Disease?
- Author
-
Joseph P. McGuirk, Neil Dunavin, Meizhang Li, and Ajoy Dias
- Subjects
0301 basic medicine ,medicine.medical_treatment ,Medicine (miscellaneous) ,Disease ,Review ,exosomes ,adoptive ,General Biochemistry, Genetics and Molecular Biology ,cell- and tissue-based therapy ,03 medical and health sciences ,Acute graft versus host disease ,medicine ,graft vs. host disease ,Effective treatment ,lcsh:QH301-705.5 ,business.industry ,Mechanism (biology) ,Mesenchymal stem cell ,Immunotherapy ,Microvesicles ,030104 developmental biology ,lcsh:Biology (General) ,Mechanism of action ,Immunology ,immunotherapy ,medicine.symptom ,business ,mesenchymal stromal cells ,transplantation immunology - Abstract
After more than a decade of preclinical and clinical development, therapeutic infusion of mesenchymal stromal cells is now a leading investigational strategy for the treatment of acute graft-versus-host disease (GVHD). While their clinical use continues to expand, it is still unknown which of their immunomodulatory properties contributes most to their therapeutic activity. Herein we describe the proposed mechanisms, focusing on the inhibitory activity of mesenchymal stromal cells (MSCs) at immunologic checkpoints. A deeper understanding of the mechanism of action will allow us to design more effective treatment strategies.
- Published
- 2017